Study: Efficacy of RSV Vaccine in Adults
The bivalent prefusion F respiratory syncytial virus (RSVpreF) vaccine is effective against symptomatic RSV infection and viral shedding, new research in the New England Journal of Medicine found.
The bivalent prefusion F respiratory syncytial virus (RSVpreF) vaccine is effective against symptomatic RSV infection and viral shedding, new research in the New England Journal of Medicine found.
The National Foundation for Infectious Diseases issued a report that addresses the impact of RSV and called for more awareness of respiratory syncytial virus.
Increases in temperature and rainfall could make outbreaks of influenza and respiratory syncytial virus less severe but more common.
RSV F is a respiratory syncytial virus F protein recombinant nanoparticle vaccine for infants via maternal immunization.
Read MoreRespiratory syncytial virus (RSV) can increase risk of cardiovascular complications for individuals with and without preexisting cardiovascular disease.
Read MorePregnant women infected with respiratory syncytial virus (RSV) can transmit the bug from their respiratory tract to the lungs of their unborn baby – resulting in altered immunity development after birth.
Read MoreThe Rocky Mountain Hospital for Children in Denver is currently “packed with children” suffering from respiratory syncytial virus (RSV).
Read MoreA phase 2a challenge study for GS-5806, an investigational oral RSV fusion inhibitor, found that the drug safely reduced the viral load and clinical illness of healthy adult volunteers who were intranasally infected with respiratory syncytial virus.
Read MoreNew devices are continuing the life-saving impact of bubble CPAP technology, which, since 1973, has saved thousands of newborns with severe respiratory illnesses.
Read MoreThrough trials with mice, researchers believe red ginseng extract improves the survival of human lung epithelial cells infected with the influenza A virus.
Read MoreA collaborative group of researchers say they have developed double-stapled peptides that inhibit respiratory syncytial virus (RSV) in cells and in mice.
Read MoreThe discovery could lead to new therapies and better diagnostics, resulting in fewer hospitalizations of children with respiratory syncytial virus, the most common cause of admission in children under the age of 1.
Read MoreResearchers have found lower respiratory tract infections caused by viruses, especially respiratory syncytial virus, are the most common dangerous conditions in newborns.
Read MoreStudy results may offer a novel approach to treating respiratory syncytial virus (RSV).
Read More